Enterome said it would use the Series A financing to initiate industrial partnerships in the pharmaceutical and nutrition fields and strengthen its development capabilities.
A new management team at the company has been formed from former founders and executives of Fovea Pharmaceuticals, which was acquired by Sanofi in 2009, and several biomarker specialists.
Bernard Gilly has also been appointed as the new chairman of the board.
Enterome CEO Pierre Belichard said, “The series A round investors – Seventure and Lundbeckfond Ventures – were specifically attracted to Enterome due to the unique nature of its technology, the close relationship to INRA and the opportunity to create unique biomarker diagnostic products meeting unmet medical and market needs.
Copyright © 2012 AltAssets